Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.

× No keyword cloud information.

45 in total

1. Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors.

Authors: A Stathis; D Hess; R von Moos; K Homicsko; G Griguolo; M Joerger; M Mark; C J Ackermann; S Allegrini; C V Catapano; A Xyrafas; M Enoiu; S Berardi; P Gargiulo; C Sessa
Journal: Invest New Drugs Date: 2017-03-20 Impact factor: 3.850

2. Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.

Authors: Rachel N Grisham; Kathleen N Moore; Michael S Gordon; Wael Harb; Gwendolyn Cody; Darragh F Halpenny; Vicky Makker; Carol A Aghajanian
Journal: Clin Cancer Res Date: 2018-05-29 Impact factor: 12.531

Review 3. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.

Authors: Carolyn E Haunschild; Krishnansu S Tewari
Journal: Future Oncol Date: 2019-11-20 Impact factor: 3.404

Review 4. Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment.

Authors: Bin Ai; Zhixin Bie; Shuai Zhang; Ailing Li
Journal: Am J Cancer Res Date: 2016-08-01 Impact factor: 6.166

Review 5. Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.

Authors: Masaki Mandai; Junzo Hamanishi; Kaoru Abiko; Noriomi Matsumura; Tsukasa Baba; Ikuo Konishi
Journal: Int J Clin Oncol Date: 2016-03-11 Impact factor: 3.402

Review 6. Ovarian cancer.

Authors: Ursula A Matulonis; Anil K Sood; Lesley Fallowfield; Brooke E Howitt; Jalid Sehouli; Beth Y Karlan
Journal: Nat Rev Dis Primers Date: 2016-08-25 Impact factor: 52.329

7. Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.

Authors: Joyce F Liu; Isabelle Ray-Coquard; Frederic Selle; Andrés M Poveda; David Cibula; Hal Hirte; Felix Hilpert; Francesco Raspagliesi; Laurence Gladieff; Philipp Harter; Salvatore Siena; Josep Maria Del Campo; Isabelle Tabah-Fisch; Joseph Pearlberg; Victor Moyo; Kaveh Riahi; Rachel Nering; William Kubasek; Bambang Adiwijaya; Akos Czibere; R Wendel Naumann; Robert L Coleman; Ignace Vergote; Gavin MacBeath; Eric Pujade-Lauraine
Journal: J Clin Oncol Date: 2016-10-23 Impact factor: 44.544

Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.